Aktienanalyse zu Cerenome, Inc. (CNSY)CNSYCerenome, Inc.

Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.

Plus Therapeutics Inc is not a good buy right now due to its significant price decline and negative financial indicators. The current price is $0.64, which is 83.39% lower year-to-date, and the RSI is at a very low 8.87, indicating oversold conditions. The forward P/E ratio is 0.97, suggesting that the stock is undervalued, but the risks are substantial, including a projected EPS of -0.98 for the next earnings report on November 12, 2026, and a 5-day change of -62.19%.